Preservative-Free Timolol maleate — Competitive Intelligence Brief

Preservative-Free Timolol maleate (Preservative-Free Timolol maleate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-selective beta-adrenergic antagonist. Area: Ophthalmology.

phase 3 Non-selective beta-adrenergic antagonist Beta-1 and beta-2 adrenergic receptors Ophthalmology Small molecule

Target snapshot

Preservative-Free Timolol maleate (Preservative-Free Timolol maleate) — Merck Sharp & Dohme LLC. Timolol maleate is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Preservative-Free Timolol maleate TARGET	Preservative-Free Timolol maleate	Merck Sharp & Dohme LLC	phase 3	Non-selective beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
Hydrocortisone/ Placebo and Propranolol	Hydrocortisone/ Placebo and Propranolol	University of Dundee	marketed	Glucocorticoid + Beta-blocker combination	Glucocorticoid receptor; Beta-1 and Beta-2 adrenergic receptors
Timolol 0.5% Ophthalmic Solution	Timolol 0.5% Ophthalmic Solution	University of California, Davis	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
RASi plus carvedilol	RASi plus carvedilol	Federal University of Minas Gerais	marketed	ACE inhibitor or ARB combined with non-selective beta-blocker	Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor
Timolol 0.25% Ophthalmic Solution	Timolol 0.25% Ophthalmic Solution	Keith G. LeBlanc, Jr, MD	marketed	Beta-adrenergic antagonist (non-selective beta-blocker)	Beta-1 and beta-2 adrenergic receptors
oral Propranolol	oral Propranolol	Ahmed talaat ahmed aly	marketed	Non-selective beta-adrenergic antagonist (beta-blocker)	Beta-1 and beta-2 adrenergic receptors
tafluprost and dorzolamide/timolol	tafluprost and dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination	Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-selective beta-adrenergic antagonist class)

1. Allergan · 1 drug in this class
2. Merck Sharp & Dohme LLC · 1 drug in this class
3. MetroHealth Medical Center · 1 drug in this class